bispecific antibody (CD20-CD3)

CD20-CD3 bispecific antibodies (BsAbs) are a class of T-cell engaging immunotherapies designed to treat B-cell malignancies, such as large B-cell lymphoma (LBCL) and follicular lymphoma. These molecules possess dual binding specificity: one arm targets the CD20 antigen, which is highly expressed on the surface of mature B-cells and most B-cell lymphomas, while the other arm targets the CD3 subunit of the T-cell receptor complex. By bridging these two cell types, the BsAb facilitates the formation of an immunological synapse, leading to the activation, proliferation, and directed cytotoxic activity of T-cells against the CD20-positive tumor cells, independent of major histocompatibility complex (MHC) recognition. Several agents in this class, including mosunetuzumab, glofitamab, and epcoritamab, have received regulatory approval for various lymphoma indications.

Other names

CD20-CD3 BsAbCD-20-CD3 BsAbCD 20-CD3 BsAbCD20xCD3 bispecific antibodyCD-20xCD3 bispecific antibodyCD 20xCD3 bispecific antibodyanti-CD20/CD3 bispecific antibodyCD20/CD3 T-cell engager